… be more effective than castration alone in the treatment of advanced prostate cancer [9,10].
Thus, … of clinical development, from phase I dose-ranging trials through phase III clinical trials. …

… This review summarizes the key clinical data, including ongoing trials, for … clinical development
of darolutamide, a novel, nonsteroidal AR antagonist currently in phase III development …

… for prostate cancer does not support an inherent resistance to the development of clinical
prostate cancer … In contrast to the increase in clinical prostate cancer cases, the prevalence of …

… extensively studied in the clinic. We review the genomic landscape of prostate cancer and
implications for clinical research in this disease. … Wnt inhibitors are in clinical development. …

… may play in prostate cancer development is independent of … (OR) of 2.5 for developing prostate
cancer in men with a first-… a predisposition for developing prostate cancer. Large genome-…

… Recent interest in the LHRH axis has centered around the clinical development of LHRH
antagonists. Since 1972, hundreds of antagonists have been synthesized and tested in animals …

… (CRPC) is now the second most common cause of male cancer-related mortality. Although
… to the development of new drugs and many new agents are now in clinical development. …

… Because of its activity in CRPC xenograft models and its favorable druglike properties,
MDV3100 was selected for clinical development. In an ongoing Phase I/II clinical trial, 30 men …

… Prostate cancer is the second most common cancer in men worldwide 1 . Outcomes for
patients with early-stage prostate cancer (stage I/II) are good, with over 90% progression-free …

… in recent years in prostate cancer risk assessment. … development, should be expected in
the coming years to yield further improvements in clinicians' ability to diagnose prostate cancer …